Biomarkers and Precision Oncology Forum 2026 to Feature Agnostic Molecular Tumor Board and Leading Experts in Singapore
Key Insights
The Biomarkers and Precision Oncology Forum (BPOF) 2026 will host an Agnostic Molecular Tumor Board segment on July 30, 2026, in Singapore, where molecular profiles guide clinical decisions over organ of origin.
Moderator Dr. Nitesh Rohatgi will lead panelists Dr. Aparna Dhar, Dr. Chiang Jianbang, Dr. Jason Chan, and Dr. Tan Ya Hwee in deliberating complex cases through a tumour-agnostic lens.
Featured speakers include Dr. Shaheenah Dawood on endocrine therapy in HR+ breast cancer (search), Dr. Jianbang Chiang on NF1/NF2 targeted therapeutics, and Dr. Tan Ya Hwee on cell therapy in solid tumors.
The Biomarkers and Precision Oncology Forum (BPOF) 2026 is set to convene leading voices in precision oncology in Singapore, featuring a landmark interactive segment—the Agnostic Molecular Tumor Board—alongside a roster of distinguished speakers addressing the latest advances in targeted therapeutics, endocrine therapy, and cell therapy for solid tumors.
The forum, scheduled for July 30, 2026, at Academia, Singapore, is accredited for 4 CME credits by the Singapore Medical Council and 4 CPE credits by the Singapore Nursing Board.
Agnostic Molecular Tumor Board: Where the Molecule Speaks Louder Than the Map
A centerpiece of BPOF 2026, the Agnostic Molecular Tumor Board will run from 10:05 to 10:30 HRS (SGT), bringing together oncologists, molecular pathologists, and precision medicine specialists to deliberate complex cases through a tumour-agnostic lens. In this paradigm, the molecular profile—not the organ of origin—guides clinical decision-making.
The session will be moderated by Dr. Nitesh Rohatgi (India) and features an expert panel comprising Dr. Aparna Dhar (India), Dr. Chiang Jianbang (Singapore), Dr. Jason Chan (Singapore), and Dr. Tan Ya Hwee (Singapore).
As the forum organizers note: "In precision oncology, the molecule often speaks louder than the map."
Featured Speakers and Key Sessions
BPOF 2026 has announced a distinguished speaker lineup addressing some of the most pressing topics in modern oncology:
-
Dr. Shaheenah Dawood from Mediclinic City Hospital (search), UAE, will present "The Evolving Field of Endocrine Therapy in HR+ Breast Cancer (search) in 2026: Questions We Will Ask in the Community," offering a forward-looking perspective on breast cancer treatment.
-
Dr. Jianbang Chiang from the National Cancer Centre Singapore will deliver a session titled "Targeted Therapeutics in NF1 (selumetinib) and NF2," exploring the latest advances in targeted treatment strategies for neurofibromatosis.
-
Dr. Ya Hwee Tan, also from the National Cancer Centre Singapore, will present "Cell Therapy in Solid Tumour," a deep dive into one of the most exciting frontiers in modern oncology.
Registration and Continuing Education
Healthcare professionals interested in attending BPOF 2026 can register now, with a 20% discount available using the code BPOFDISC20. The forum's CME and CPE accreditation underscores its educational value for both physicians and nursing professionals engaged in precision oncology practice.